Johnson & Johnson (NYSE: JNJ) announced that it received FDA approval for its Tecnis PureSee intraocular lens (IOL) for cataract surgery.
The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...
Johnson & Johnson (JNJ) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its Tecnis PureSee intraocular lens (IOL), giving eye surgeons a new lens option for use in ...
Johnson & Johnson (NYSE:JNJ) received FDA approval for its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract patients. The lens is described as the first of its kind in the ...
CPT copyright 2011 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Editor’s Note: This article ...
GlobalData on MSN
FDA approves J&J’s TECNIS PureSee intraocular lens
The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.
Intraocular lens insertion for correction of refractive error, with preservation of the natural lens
Refractive errors can usually be corrected by wearing spectacles or contact lenses. Surgical treatments include photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK) and insertion of ...
FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...
Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients ...
Unlike traditional EDOF lenses, Lucidis® delivers full-range visual performance comparable to a premium trifocal IOL without disturbances.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results